Fatality Sparks Swiss Recall of AMAG’s Anemia Drug

A patient death and safety reports of hypersensitivity reactions to AMAG Pharmaceuticals’ flagship iron deficiency drug Rienso has prompted a one-batch recall. The recall, specific to the Swiss market, was based on four reports of adverse events related to the ferumoxytol-based drug, according to an SEC filing.
Washington Drug Letter